Clorox (NYSE:CLX) Given New $147.00 Price Target at Deutsche Bank Aktiengesellschaft
Clorox (NYSE:CLX) Given New $147.00 Price Target at Deutsche Bank Aktiengesellschaft
Clorox (NYSE:CLX – Get Rating) had its target price cut by Deutsche Bank Aktiengesellschaft from $152.00 to $147.00 in a research note published on Monday, The Fly reports.
CLX has been the topic of a number of other research reports. Raymond James upped their price target on shares of Clorox from $160.00 to $165.00 and gave the company an outperform rating in a research note on Friday, February 3rd. StockNews.com assumed coverage on shares of Clorox in a report on Thursday, March 16th. They issued a hold rating on the stock. Jefferies Financial Group upped their price objective on shares of Clorox from $140.00 to $145.00 and gave the company a hold rating in a report on Wednesday, February 1st. JPMorgan Chase & Co. upped their price objective on shares of Clorox from $126.00 to $135.00 and gave the company an underweight rating in a report on Friday, January 13th. Finally, Wells Fargo & Company upped their price objective on shares of Clorox from $125.00 to $135.00 and gave the company an underweight rating in a report on Tuesday, January 3rd. Seven research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $141.00.
Get Clorox alerts:Clorox Trading Down 0.0 %
NYSE CLX opened at $154.61 on Monday. The company has a quick ratio of 0.47, a current ratio of 0.86 and a debt-to-equity ratio of 5.04. The firm has a market cap of $19.10 billion, a PE ratio of 44.17, a price-to-earnings-growth ratio of 3.16 and a beta of 0.29. The company has a 50 day moving average price of $150.33 and a 200 day moving average price of $144.84. Clorox has a 52 week low of $120.50 and a 52 week high of $160.59.
Clorox (NYSE:CLX – Get Rating) last issued its quarterly earnings results on Thursday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.32. Clorox had a net margin of 6.16% and a return on equity of 89.97%. The business had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.66 billion. During the same quarter in the prior year, the business posted $0.66 EPS. Clorox's revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Clorox will post 4.23 EPS for the current fiscal year.
Clorox Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 12th. Shareholders of record on Wednesday, April 26th will be issued a dividend of $1.18 per share. This represents a $4.72 annualized dividend and a yield of 3.05%. The ex-dividend date of this dividend is Tuesday, April 25th. Clorox's payout ratio is 134.86%.
Hedge Funds Weigh In On Clorox
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. OLD Mission Capital LLC purchased a new position in Clorox during the fourth quarter valued at $29,000. Regal Investment Advisors LLC raised its position in shares of Clorox by 0.5% in the fourth quarter. Regal Investment Advisors LLC now owns 16,196 shares of the company's stock valued at $2,273,000 after buying an additional 84 shares during the last quarter. Voya Investment Management LLC raised its position in shares of Clorox by 1.0% in the fourth quarter. Voya Investment Management LLC now owns 73,600 shares of the company's stock valued at $10,328,000 after buying an additional 732 shares during the last quarter. Natixis raised its position in shares of Clorox by 1,416.6% in the fourth quarter. Natixis now owns 115,016 shares of the company's stock valued at $16,140,000 after buying an additional 107,432 shares during the last quarter. Finally, Kovack Advisors Inc. raised its position in shares of Clorox by 2.7% in the fourth quarter. Kovack Advisors Inc. now owns 3,002 shares of the company's stock valued at $421,000 after buying an additional 79 shares during the last quarter. 79.12% of the stock is owned by hedge funds and other institutional investors.
About Clorox
(Get Rating)
The Clorox Co engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States.
Read More
- Get a free copy of the StockNews.com research report on Clorox (CLX)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Carvana May Be Able To Reach Profitability This Year
- Low Volume Bunge Plunge Presents an Opportunity
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
高樂氏(紐約證券交易所代碼:CLX-GET評級)據The Fly報道,德意志銀行在週一發佈的一份研究報告中將其目標價從152.00美元下調至147.00美元。
CLX一直是其他一些研究報告的主題。2月3日,雷蒙德·詹姆斯在一份研究報告中將高樂氏股票的目標價從160.00美元上調至165.00美元,並給出了表現優於大盤的評級。斯托克新聞網在3月16日星期四的一份報告中對高樂氏的股票進行了報道。他們對這只股票發佈了持有評級。傑富瑞金融集團將高樂氏股票的目標價從140.00美元上調至145.00美元,並在2月1日週三的一份報告中給予該公司持有評級。摩根大通在1月13日的一份報告中將高樂氏股票的目標價從126.00美元上調至135.00美元,並對該公司進行了減持評級。最後,富國銀行將高樂氏股票的目標價從125.00美元上調至135.00美元,並在1月3日(星期二)的一份報告中對該公司進行了減持評級。7位研究分析師對該股的評級為賣出,6位分析師對該公司股票的評級為持有,1位分析師對該公司股票的評級為買入。根據MarketBeat.com的數據,該股目前的平均評級為持有,平均目標價為141.00美元。
到達高樂氏警報:高樂氏股價下跌0.0%
紐約證交所CLX週一開盤報154.61美元。該公司的速動比率為0.47,流動比率為0.86,債務權益比率為5.04。該公司市值為191億美元,本益比為44.17倍,本益比為3.16倍,貝塔係數為0.29。該公司的50日移動均線價格為150.33美元,200日移動均線價格為144.84美元。高樂氏的52周低點為120.50美元,52周高位為160.59美元。
高樂氏(紐約證券交易所代碼:CLX-GET Rating)最近一次發佈季度收益報告是在2月2日星期四。該公司公佈本季度每股收益(EPS)為0.98美元,高於分析師普遍預期的0.66美元和0.32美元。高樂氏的淨利潤率為6.16%,股本回報率為89.97%。該業務本季度營收為17.2億美元,而分析師預期為16.6億美元。在前一年的同一季度,該業務公佈的每股收益為0.66美元。與去年同期相比,高樂氏本季度的收入增長了1.4%。賣方分析師預測,作為一個整體,高樂氏本財年每股收益將達到4.23歐元。
高樂氏宣佈分紅
該公司最近還披露了季度股息,將於5月12日(星期五)支付。4月26日(星期三)登記在冊的股東將獲得每股1.18美元的股息。這意味著年化股息為4.72美元,收益率為3.05%。本次股息除息日期為4月25日(星期二)。高樂氏的派息率為134.86。
對沖基金看好高樂氏
幾家對沖基金和其他機構投資者最近增持或減持了該股。舊使命資本有限責任公司在第四季度購買了一個新的高樂氏頭寸,價值29,000美元。富豪投資顧問公司(Regal Investment Advisors LLC)在第四季度將其在高樂氏股票的持倉提高了0.5%。富豪投資顧問公司現在持有16,196股該公司股票,價值2,273,000美元,在上個季度又購買了84股。Voya Investment Management LLC在第四季度將其在Clorox股票的持倉提高了1.0%。Voya Investment Management LLC現在擁有該公司73,600股股票,價值10,328,000美元,上個季度又購買了732股。Natixis在第四季度將其在Clorox股票的頭寸提高了1416.6%。Natixis現在擁有115,016股該公司的股票,價值16,140,000美元,在上個季度又購買了107,432股。最後,Kovack Advisors Inc.在第四季度將其在高樂氏股票的持倉量提高了2.7%。科瓦克顧問公司(Kovack Advisors Inc.)現在持有該公司3,002股股票,價值421,000美元,上一季度又購買了79股。79.12%的股票由對沖基金和其他機構投資者持有。
關於高樂氏
(獲取評級)
高樂氏公司從事消費品和專業產品的製造和營銷。它通過以下業務部門運營:健康和健康、家庭、生活方式和國際。健康和健康部分包括清潔產品、專業產品和維生素、礦物質和補充劑,主要在美國銷售和銷售。
閱讀更多內容
- 免費獲取StockNews.com關於高樂氏的研究報告
- KB Home強勁業績提振價格
- 咀嚼股票正在為長期盈利增長做準備
- 華爾街為什麼喜歡這3便士股票
- Carvana今年可能實現盈利
- 低成交量捆綁暴跌帶來機遇
接受《高樂氏日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Clorox和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧